Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_1
3
60%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(3)
Other(1)

Detailed Status

Withdrawn2
Terminated1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (25.0%)
Phase 13 (75.0%)

Trials by Status

terminated120%
unknown120%
withdrawn240%
completed120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

PVSRIPO for Patients With Unresectable Melanoma

NCT03712358
completedearly_phase_1

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

NCT03564782
unknown

EAP for the Treatment of Glioblastoma With PVSRIPO

NCT04599647
withdrawnphase_1

PVSRIPO in Combination With Nivolumab in Melanoma

NCT04125719
withdrawnphase_1

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

NCT03973879

Clinical Trials (5)

Showing 5 of 5 trials
NCT03712358Phase 1

PVSRIPO for Patients With Unresectable Melanoma

Terminated
NCT03564782Early Phase 1

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

Completed
NCT04599647

EAP for the Treatment of Glioblastoma With PVSRIPO

Unknown
NCT04125719Phase 1

PVSRIPO in Combination With Nivolumab in Melanoma

Withdrawn
NCT03973879Phase 1

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5